Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency 3Kidney Failure, Chronic 3Multiple Myeloma 2Carcinoma, Renal Cell 2Virus Diseases 1Renal Insufficiency, Chronic 1Kidney Diseases 1Hematologic Neoplasms 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 10Valganciclovir 6Etoposide 4Doxorubicin 4Valacyclovir 3Gemcitabine 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3spartalizumab 2pembrolizumab 2pegaspargase 2Zidovudine 2Vincristine 2Radiotherapy, Intensity-Modulated 2Prednisone 2Methylprednisolone 2Methotrexate 2Matrix-M 2Leucovorin 2Lenalidomide 2Cell Count 2Carboplatin 2Blood Specimen Collection 2Acyclovir 2valomaciclovir 1toripalimab 1threonic acid 1ruxolitinib 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Epstein-Barr Virus Infections × Kidney Transplantation × Clear all
NCT01136395 2019-10-08

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

University of Giessen

Phase 2 Completed
85 enrolled

Virus Diseases, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡